A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

NCT01495013 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2016-11-21

No results posted yet for this study

Summary

The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control (glycated haemoglobin, HbA1c) and cholesterol levels (Low-density lipoprotein, LDL) in diabetic subjects, who are inadequately controlled on a stable dose of metformin. Eight dose combinations will be included.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

1mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

2mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

3mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

4mg Glimepiride/10mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

1mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

2mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

3mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

4mg Glimepiride/20mg Atorvastatin FDC

1 tablet by mouth once a day

DRUG

1mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

2mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

3mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

4mg Glimepiride

1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

DRUG

10mg Atorvastatin

1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

DRUG

20mg Atorvastatin

1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-04-30
Completion
2013-09-30

Countries

  • Malaysia
  • Mexico
  • Philippines
  • Russia
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01495013 on ClinicalTrials.gov